Overview

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
A Phase 1/2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In Relapsed and Refractory Multiple Myeloma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Stemline Therapeutics, Inc.
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Pomalidomide
Thalidomide